{
    "title": "108_s491",
    "content": "The Act may be cited as the \"Inflammatory Bowel Disease Act\". Crohn's disease and ulcerative colitis are serious inflammatory diseases of the gastrointestinal tract, collectively known as inflammatory bowel disease. They present symptoms such as severe diarrhea, abdominal pain, fever, and rectal bleeding. Up to 1,000,000 people in the United States are estimated to suffer from these diseases. In 1990, the annual medical costs for Crohn's disease patients were estimated at $1-1.2 billion, while for ulcerative colitis patients it was $400-600 million. Patients with inflammatory bowel disease are at high risk for colorectal cancer. SEC. 3. INFLAMMATORY BOWEL DISEASE RESEARCH EXPANSION. The Director of the National Institute of Diabetes and Digestive and Kidney Diseases will expand research on inflammatory bowel disease, focusing on genetic research, animal models, clinical studies, and other initiatives outlined in the \"Challenges in Inflammatory Bowel Disease\" document. Authorization of appropriations is provided for these research activities. Authorization of appropriations is provided for research activities related to inflammatory bowel disease. $75,000,000 is authorized for fiscal year 2004, $100,000,000 for fiscal year 2005, and additional funds for fiscal years 2006 and 2007. Up to 20 percent of the funds will be reserved for training health professionals in biomedical research focused on inflammatory bowel disease and related disorders. The Director of the Centers for Disease Control and Prevention will establish a national program to determine the prevalence of inflammatory bowel disease in the US and raise awareness. $5,000,000 is authorized for fiscal year 2004, with additional funds for fiscal years 2005 through 2007. The Institute of Medicine will conduct a study on coverage standards for various therapies under Medicare, Medicaid, and private insurance. This includes parenteral nutrition, enteral nutrition formula, medically necessary food products, ostomy supplies, and FDA-approved therapies for Crohn's disease and ulcerative colitis. The study will consider outpatient or home health care settings and a report will be submitted to Congress within 6 months of enactment. Authorization of appropriations is provided as necessary. The General Accounting Office will study the challenges faced by inflammatory bowel disease patients when applying for disability insurance benefits. Recommendations for improving the application process will be included in the report to Congress within 6 months of enactment. Authorization of appropriations is provided as necessary."
}